|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.47 EUR | +0.32% |
|
-4.27% | +4.29% |
| Dec. 05 | Eckert & Ziegler to reduce executive board size | RE |
| Dec. 03 | Eckert & Ziegler sign supply agreement with SK Biopharmaceuticals | RE |
| Capitalization | 968M 1.13B 907M 845M 1.56B 101B 1.7B 10.61B 4.1B 47.87B 4.23B 4.14B 175B | P/E ratio 2025 * |
13.8x | P/E ratio 2026 * | 19x |
|---|---|---|---|---|---|
| Enterprise value | 851M 990M 797M 743M 1.37B 89.08B 1.49B 9.32B 3.6B 42.07B 3.72B 3.64B 154B | EV / Sales 2025 * |
2.67x | EV / Sales 2026 * | 2.47x |
| Free-Float |
67.07% | Yield 2025 * |
1.13% | Yield 2026 * | 1.16% |
Last Transcript: Eckert & Ziegler SE
| 1 day | +0.32% | ||
| 1 week | -4.27% | ||
| Current month | -4.27% | ||
| 1 month | -3.73% | ||
| 3 months | -5.09% | ||
| 6 months | -31.14% | ||
| Current year | +4.29% |
| 1 week | 15.36 |  | 16.16 |
| 1 month | 14.89 | | 17.47 |
| Current year | 13.77 | | 23.25 |
| 1 year | 13.77 | | 23.25 |
| 3 years | 9.64 | | 23.25 |
| 5 years | 9.64 | | 47.13 |
| 10 years | 1.38 | | 47.13 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 58 | 2023-06-06 | |
Karolin Riehle
IRC | Investor Relations Contact | - | - |
Jan Schöpflin
SAM | Sales & Marketing | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Andreas Eckert
CHM | Chairman | 56 | 2023-06-06 |
Helmut Grothe
BRD | Director/Board Member | 65 | 2013-12-31 |
Albert Rupprecht
BRD | Director/Board Member | 57 | 2016-12-31 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 1.1% | 0 M€ | -.--% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.32% | -4.27% | -2.13% | -16.08% | 1.13B | |
| -1.05% | +1.35% | +20.04% | -30.82% | 18.41B | |
| +7.09% | +3.81% | +87.18% | +272.48% | 2.46B | |
| -0.22% | +1.50% | -26.17% | -70.34% | 1.89B | |
| -0.27% | -2.83% | +1.97% | -3.25% | 1.49B | |
| +0.44% | -3.64% | +0.76% | -41.74% | 899M | |
| +1.75% | +0.87% | +2.16% | -23.94% | 893M | |
| +1.61% | -0.67% | -19.45% | -46.86% | 676M | |
| -1.59% | +29.21% | +360.45% | - | 567M | |
| +0.35% | +0.09% | -27.72% | -43.70% | 481M | |
| Average | +0.84% | +1.74% | +39.71% | -0.47% | 2.89B | |
| Weighted average by Cap. | -0.00% | +1.03% | +24.74% | -5.83% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 318M 370M 298M 278M 513M 33.31B 558M 3.49B 1.35B 15.73B 1.39B 1.36B 57.53B | 337M 392M 316M 294M 543M 35.28B 591M 3.69B 1.43B 16.66B 1.47B 1.44B 60.93B |
| Net income | 48.9M 56.89M 45.81M 42.7M 78.86M 5.12B 85.78M 536M 207M 2.42B 214M 209M 8.84B | 51.6M 60.03M 48.34M 45.05M 83.22M 5.4B 90.52M 565M 218M 2.55B 225M 220M 9.33B |
| Net Debt | -117M -136M -110M -102M -189M -12.27B -206M -1.28B -496M -5.79B -512M -501M -21.18B | -134M -156M -126M -117M -216M -14.03B -235M -1.47B -567M -6.63B -585M -573M -24.24B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-05 | 15.47 € | +0.32% | 81,281 |
| 25-12-04 | 15.42 € | -0.52% | 45,390 |
| 25-12-03 | 15.50 € | -0.64% | 81,707 |
| 25-12-02 | 15.60 € | -2.01% | 51,142 |
| 25-12-01 | 15.92 € | -1.49% | 64,393 |
Delayed Quote Xetra, December 05, 2025 at 11:35 am EST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- EUZ Stock
Select your edition
All financial news and data tailored to specific country editions
